Literature DB >> 28541521

Informative Patterns of Health-Care Utilization Prior to the Diagnosis of Pancreatic Ductal Adenocarcinoma.

Gregory A Coté, Huiping Xu, Jeffery J Easler, Timothy D Imler, Evgenia Teal, Stuart Sherman, Murray Korc.   

Abstract

Early-detection tests for pancreatic ductal adenocarcinoma (PDAC) are needed. Since a hypothetical screening test would be applied during antecedent clinical encounters, we sought to define the variability in health-care utilization leading up to PDAC diagnosis. This was a retrospective cohort study that included patients diagnosed with PDAC in the Indianapolis, Indiana, area between 1999 and 2013 with at least 1 health-care encounter during the antecedent 36-month period (n = 1,023). Patients were classified by unique patterns of health-care utilization using a group-based trajectory model. The prevalences of PDAC signals, such as diabetes mellitus (DM) and chronic pancreatitis, were compared. Four distinct trajectories were identified, the most common (42.0%) being having few clinical encounters more than 6 months prior to PDAC diagnosis (late acceleration). In all cases, a minority of persons had DM (30.6%, with 9.5% <1.5 years before PDAC) or any pancreatic disorder (39.9%); these were least common in the late-acceleration group (DM, 14.7%; any pancreatic disorder, 32.1% (P < 0.001)). The most common pattern of antecedent care was having few clinical encounters until shortly before PDAC diagnosis. Since the majority of patients diagnosed with PDAC do not have an antecedent PDAC signal, early-detection strategies limited to these groups may not apply to the majority of cases.
© The Author(s) 2017. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  carcinoma, ductal; diabetes mellitus; pancreatic neoplasms; pancreatitis, chronic

Mesh:

Year:  2017        PMID: 28541521      PMCID: PMC5860250          DOI: 10.1093/aje/kwx168

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  19 in total

Review 1.  Early detection of sporadic pancreatic cancer: summative review.

Authors:  Suresh T Chari; Kimberly Kelly; Michael A Hollingsworth; Sarah P Thayer; David A Ahlquist; Dana K Andersen; Surinder K Batra; Teresa A Brentnall; Marcia Canto; Deborah F Cleeter; Matthew A Firpo; Sanjiv Sam Gambhir; Vay Liang W Go; O Joe Hines; Barbara J Kenner; David S Klimstra; Markus M Lerch; Michael J Levy; Anirban Maitra; Sean J Mulvihill; Gloria M Petersen; Andrew D Rhim; Diane M Simeone; Sudhir Srivastava; Masao Tanaka; Aaron I Vinik; David Wong
Journal:  Pancreas       Date:  2015-07       Impact factor: 3.327

2.  Detectable Symptomatology Preceding the Diagnosis of Pancreatic Cancer and Absolute Risk of Pancreatic Cancer Diagnosis.

Authors:  Harvey A Risch; Herbert Yu; Lingeng Lu; Mark S Kidd
Journal:  Am J Epidemiol       Date:  2015-06-06       Impact factor: 4.897

3.  Increased risk of pancreatic adenocarcinoma after acute pancreatitis.

Authors:  Satish Munigala; Fasiha Kanwal; Hong Xian; Jeffrey F Scherrer; Banke Agarwal
Journal:  Clin Gastroenterol Hepatol       Date:  2014-01-16       Impact factor: 11.382

4.  Overweight in early adulthood, adult weight change, and risk of type 2 diabetes, cardiovascular diseases, and certain cancers in men: a cohort study.

Authors:  Renée de Mutsert; Qi Sun; Walter C Willett; Frank B Hu; Rob M van Dam
Journal:  Am J Epidemiol       Date:  2014-04-30       Impact factor: 4.897

5.  Cost analysis of pancreatic carcinoma treatment.

Authors:  W Du; D Touchette; V K Vaitkevicius; W P Peters; A F Shields
Journal:  Cancer       Date:  2000-11-01       Impact factor: 6.860

6.  The cost of treating pancreatic cancer--a cohort study based on patients' records from four hospitals in Sweden.

Authors:  Jonas Hjelmgren; Jeanette Ceberg; Ulf Persson; Thor A Alvegård
Journal:  Acta Oncol       Date:  2003       Impact factor: 4.089

7.  Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) Analysis.

Authors:  Robert R McWilliams; Patrick Maisonneuve; William R Bamlet; Gloria M Petersen; Donghui Li; Harvey A Risch; Herbert Yu; Elizabeth T H Fontham; Brian Luckett; Cristina Bosetti; Eva Negri; Carlo La Vecchia; Renato Talamini; H Bas Bueno de Mesquita; Paige Bracci; Steven Gallinger; Rachel E Neale; Albert B Lowenfels
Journal:  Pancreas       Date:  2016-02       Impact factor: 3.327

8.  Burden of pancreatic cancer and disease progression: economic analysis in the US.

Authors:  Stella Chang; Stacey R Long; Lucie Kutikova; Lee Bowman; William H Crown; Gary H Lyman
Journal:  Oncology       Date:  2006-02-06       Impact factor: 2.935

9.  Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature.

Authors:  Ola Ghatnekar; Roland Andersson; Marianne Svensson; Ulf Persson; Ulrika Ringdahl; Paula Zeilon; Carl A K Borrebaeck
Journal:  Int J Cancer       Date:  2013-06-10       Impact factor: 7.396

10.  Cost-utility estimations of palliative care in patients with pancreatic adenocarcinoma: a retrospective analysis.

Authors:  David Ljungman; Anders Hyltander; Kent Lundholm
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

View more
  2 in total

1.  Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis: Summary of the Working Group on Drug Development and Trials in Recurrent Acute Pancreatitis at the National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Authors:  Mark E Lowe; Marc T Goodman; Gregory A Coté; Marshall J Glesby; Mark Haupt; Nicholas J Schork; Vikesh K Singh; Dana K Andersen; Stephen J Pandol; Aliye Uc; David C Whitcomb
Journal:  Pancreas       Date:  2018 Nov/Dec       Impact factor: 3.327

2.  Combined Versus Separate Sessions of Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for the Diagnosis and Management of Pancreatic Ductal Adenocarcinoma with Biliary Obstruction.

Authors:  Tugrul Purnak; Ihab I El Hajj; Stuart Sherman; Evan L Fogel; Lee McHenry; Glen Lehman; Mark A Gromski; Mohammad Al-Haddad; John DeWitt; James L Watkins; Jeffrey J Easler
Journal:  Dig Dis Sci       Date:  2020-08-27       Impact factor: 3.487

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.